Counterfeit Semaglutide: Advanced Spot‑the‑Fake Checklist (Photos)

The recent discovery of counterfeit Ozempic (semaglutide) injection pens in the United States drug supply chain has raised significant concerns among healthcare professionals, regulatory agencies, and patients relying on this important medication.

The U.S. Food and Drug Administration (FDA) announced in April 2025 that several hundred units of counterfeit Ozempic 1mg had been identified and subsequently seized within the legitimate drug supply chain, marking a developing situation in the ongoing effort to protect consumers from falsified medications.

These counterfeit products represent a serious threat to patient safety, as they bypass the rigorous quality controls and manufacturing standards required for FDA-approved pharmaceuticals.

This article provides a comprehensive overview of the current situation, outlines specific identification strategies, details the potential health risks, and offers practical guidance for ensuring medication safety, creating a protective framework from verification to response.

Key Takeaways

• Counterfeit Ozempic pens have been discovered in legitimate U.S. drug supply chains, posing serious safety risks to patients.
• Fake pens can be identified by poor labeling, text inconsistencies, or spelling errors on packaging.
• The FDA confirmed counterfeit lots PAR0362 (serials starting 51746517) and NAR0074 (serial 430834149057), urging verification with Novo Nordisk.
• Counterfeit needles are unsterile and can cause severe infections such as abscesses, sepsis, or endocarditis.
• Patients should only buy Ozempic from licensed pharmacies, inspect packaging, and avoid online or discounted sellers.
• Suspected counterfeit products should be reported immediately to the FDA, MedWatch, and Novo Nordisk.
• Vigilance and reporting from patients and healthcare professionals are crucial in combating counterfeit drug distribution.

Key Visual Red Flags of Counterfeit Ozempic Pens

Vigilant visual inspection represents the first line of defense against counterfeit medications. Regulatory authorities have identified specific anomalies in the counterfeit Ozempic pens that distinguish them from authentic products. The World Health Organization has noted that falsified Ozempic pens may display a scale extending out from the pen body when setting the dose, a feature not present in genuine devices.

Additionally, the label quality often appears inferior and may not adhere properly to the pen surface. Upon closer examination, the packaging may contain typographic inconsistencies including variations in spacing, font weight, and alignment compared to legitimate products. The Australian Therapeutic Goods Administration specifically noted differences in "spacing and bolding of the text" in recent counterfeit interceptions.

Perhaps most obviously, some counterfeit cartons display spelling mistakes or grammatical errors on the packaging—flaws that would never appear in Novo Nordisk's authentic products. These visual indicators, while sometimes subtle, provide critical warning signs that warrant further verification before use.

Verify Immediately: How to Check Lot and Serial Numbers

Beyond visual inspection, precise verification of product identifiers offers the most reliable method for detecting counterfeit Ozempic. Regulatory authorities have identified specific lot and serial number combinations confirmed as counterfeit. The FDA advises patients, healthcare professionals, and pharmacies to immediately check any Ozempic 1mg products in their possession and not use, distribute, or sell products matching the following identifiers:

• Lot number PAR0362 with serial numbers beginning with the first eight digits 51746517 (identified April 2025)
• Lot number NAR0074 with serial number 430834149057 (identified December 2023)

The distinction between authentic and counterfeit identifiers can be confusing for consumers. Notably, some counterfeit products utilize genuine lot numbers but pair them with fraudulent serial numbers. This sophisticated approach to duplication requires careful attention to both identifiers simultaneously.

The manufacturer Novo Nordisk maintains comprehensive verification resources, and patients with concerns can contact Novo Nordisk customer care directly at 1-800-727-6500 for assistance with product authentication. This verification step becomes particularly crucial during periods of medication shortage when counterfeiters often exploit supply gaps to introduce fraudulent products into the market.

The Hidden Danger: Infection Risks from Unsterile, Counterfeit Needles

While much attention focuses on the drug formulation itself, the associated needles in counterfeit Ozempic packages present equally serious health concerns. The FDA has confirmed through laboratory analysis that "the needles from the samples are counterfeit," meaning their sterility cannot be confirmed.

This contamination risk creates a pathway for localized and systemic infections that could complicate existing health conditions. The use of non-sterile injection equipment introduces potential exposure to bacterial and fungal pathogens that can lead to abscess formation at the injection site, bloodstream infections (sepsis), or even endocarditis in vulnerable patients.

These infection risks compound the uncertainties regarding the actual composition of the liquid medication within the counterfeit devices. Unlike the known side effect profile of authentic semaglutide—which commonly includes predictable gastrointestinal symptoms like nausea, vomiting, diarrhea, abdominal pain and constipation—the consequences of using unsterile injection equipment can be severe and potentially life-threatening, requiring immediate medical intervention.

Protect Yourself: A Safe Purchasing Checklist for Consumers

Ensuring the authenticity of prescription medications requires deliberate purchasing practices and heightened awareness of distribution channels. The FDA emphasizes that patients should only obtain Ozempic with a valid prescription through state-licensed pharmacies, avoiding online platforms that do not require appropriate medical oversight. When acquiring medications, consider the following protective measures:

• Verify Pharmacy Legitimacy: Confirm that your pharmacy holds proper state licensing and utilizes authorized distributors. The FDA's BeSafeRx campaign provides resources for identifying legitimate online pharmacies.
• Examine Upon Receipt: Carefully inspect medication packaging for the visual red flags previously mentioned before accepting delivery.
• Question Unrealistic Pricing: Be wary of prices significantly below market average, as counterfeiters often use discounted pricing to liquidate fraudulent products quickly.
• Consult Healthcare Providers: Discuss medication sources with your prescribing physician, who can often recommend reputable pharmacies with reliable supply chains.
• Avoid Informal Networks: Never purchase prescription medications from online marketplaces, social media platforms, or unauthorized intermediaries, regardless of their claims.

Particular caution applies to online offers for weight loss medications, as the FBI has issued separate warnings about fake compounded weight loss drugs being marketed directly to consumers.

The convergence of medication shortages and high consumer demand creates ideal conditions for counterfeiters to exploit desperate patients through seemingly convenient but dangerous unauthorized channels.

Found a Fake? Here's How and Why to Report It

Discovering a potentially counterfeit product necessitates immediate reporting to appropriate regulatory and law enforcement agencies, creating a vital opportunity to protect others from similar risks.

The FDA emphasizes that "suspected counterfeit products may be reported to FDA by calling your local FDA consumer complaint coordinator or by reporting it directly at report suspected criminal activity." If you suspect you have encountered counterfeit Ozempic:

1. Stop Using Immediately: Discontinue use of the suspected product and secure it in a safe location.
2. Contact Healthcare Provider: Inform your physician about your concerns and seek guidance on alternative treatment options.
3. Report to Appropriate Channels: Notify both the FDA and Novo Nordisk, providing specific lot and serial numbers, purchase details, and photographs if possible.
4. Report Adverse Events: If you have already used the product and experienced any health effects, report these to the FDA's MedWatch Safety Information and Adverse Event Reporting Program, even if symptoms seem minor.

The regulatory response to previous counterfeit discoveries demonstrates the critical importance of these reports. The FDA's seizure of thousands of units of counterfeit Ozempic in

December 2023 was facilitated by earlier consumer and healthcare professional reports. Additionally, patients and professionals should report any adverse events through FDA's MedWatch program either online through the MedWatch Online Voluntary Reporting Form or by downloading, completing, and faxing the form to 1-800-FDA-0178.

These reports contribute to a surveillance network that enables rapid regulatory response to protect public health. As noted in the FDA's warning, "Your report may be the critical action that prompts a modification in use or design of the product, improves its safety profile and leads to increased patient safety."